N/A N=2,511 Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis
Psoriasis
Primary: Five-year Cumulative Incidence of Serious Adverse Events and Serious Infectious Events — 0.2029; 0.0581 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
Phase 3 N=374 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: SCR (Seroconversion Rate) at Day 56 — 41.2; 97.3; 25.6 percentage of participants — p=>0.99
Phase 3 N=529 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Meningococcal Disease
Primary: Percentage of Subjects With hSBA Titer ≥1:8 Against Serogroup A, C, W and Y One Month After Toddler Vaccination of MenACWY-CRM — 2; 1; 89; 2 Percentage of subjects
Phase 3 N=77 Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
Varicose Veins
Primary: The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks — 16.7; 30.7 units on a scale
Phase 2 N=51 Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
Typhoid Fever
Primary: Anti-Vi ELISA Geometric Mean Concentration (GMC) — 35; 31; 3.22 ELISA Units/mL
Phase 2 N=55 The Effects of DHA on Periodontitis
Periodontitis · Gingivitis · Inflammation
Primary: Change in Pocket Depth (mm) — -0.71; -0.54 mm — p=<0.05
Phase 3 N=1,010 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Survival — 10.0; 10.4 months — p=0.0007
N/A N=21,953 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Cabergoline Prescriptions by Database and Indication: Year 1 — 17; 1782; 6; 293 prescriptions
N/A N=834 Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)
Type 2 Diabetes Mellitus
Primary: Number of Participants Achieving Hemoglobin A1C (HbA1C) <7% — 378 participants
N/A N=73 Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women
Contraception
Primary: Provider Perceived Ease of Insertion on a 100 Point Visual Analogue Scale — 21; 21 units on a scale
N/A N=8 Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
HIV Infections
Primary: Absolute CD4 and CD4 % — 8 participants
Phase 2 N=51 Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer · Non-Small Cell Lung Cancer
Primary: Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1 — 0.75; 1.0; 0.75; 1.5 hours
Phase 4 N=35 Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.
Acne Prone Skin
Primary: Cutaneous Tolerability Based on Visual Inspection - Erythema — 29; 33; 30; 29 participants
Phase 3 N=4,545 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Meningitis, Meningococcal
Primary: Percentage of Subjects With hSBA Titer >=1:8 - US Subjects — 94; 72; 98; 90 Percentages of subjects